359 related articles for article (PubMed ID: 18643796)
1. Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment.
Hill MN; Carrier EJ; McLaughlin RJ; Morrish AC; Meier SE; Hillard CJ; Gorzalka BB
J Neurochem; 2008 Sep; 106(6):2322-36. PubMed ID: 18643796
[TBL] [Abstract][Full Text] [Related]
2. Electroconvulsive shock treatment differentially modulates cortical and subcortical endocannabinoid activity.
Hill MN; Barr AM; Ho WS; Carrier EJ; Gorzalka BB; Hillard CJ
J Neurochem; 2007 Oct; 103(1):47-56. PubMed ID: 17561935
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of the antidepressants tranylcypromine and fluoxetine on limbic cannabinoid receptor binding and endocannabinoid contents.
Hill MN; Ho WS; Hillard CJ; Gorzalka BB
J Neural Transm (Vienna); 2008 Dec; 115(12):1673-9. PubMed ID: 18974922
[TBL] [Abstract][Full Text] [Related]
4. Involvement of the endocannabinoid system in the ability of long-term tricyclic antidepressant treatment to suppress stress-induced activation of the hypothalamic-pituitary-adrenal axis.
Hill MN; Ho WS; Sinopoli KJ; Viau V; Hillard CJ; Gorzalka BB
Neuropsychopharmacology; 2006 Dec; 31(12):2591-9. PubMed ID: 16710317
[TBL] [Abstract][Full Text] [Related]
5. Dysregulation of the endogenous cannabinoid system in adult rats prenatally treated with the cannabinoid agonist WIN 55,212-2.
Castelli MP; Paola Piras A; D'Agostino A; Pibiri F; Perra S; Gessa GL; Maccarrone M; Pistis M
Eur J Pharmacol; 2007 Nov; 573(1-3):11-9. PubMed ID: 17644084
[TBL] [Abstract][Full Text] [Related]
6. Suppression of amygdalar endocannabinoid signaling by stress contributes to activation of the hypothalamic-pituitary-adrenal axis.
Hill MN; McLaughlin RJ; Morrish AC; Viau V; Floresco SB; Hillard CJ; Gorzalka BB
Neuropsychopharmacology; 2009 Dec; 34(13):2733-45. PubMed ID: 19710634
[TBL] [Abstract][Full Text] [Related]
7. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis.
Cabranes A; Venderova K; de Lago E; Fezza F; Sánchez A; Mestre L; Valenti M; García-Merino A; Ramos JA; Di Marzo V; Fernández-Ruiz J
Neurobiol Dis; 2005 Nov; 20(2):207-17. PubMed ID: 16242629
[TBL] [Abstract][Full Text] [Related]
8. Prolonged glucocorticoid treatment decreases cannabinoid CB1 receptor density in the hippocampus.
Hill MN; Carrier EJ; Ho WS; Shi L; Patel S; Gorzalka BB; Hillard CJ
Hippocampus; 2008; 18(2):221-6. PubMed ID: 18058925
[TBL] [Abstract][Full Text] [Related]
9. Deficiency in endocannabinoid signaling in the nucleus accumbens induced by chronic unpredictable stress.
Wang W; Sun D; Pan B; Roberts CJ; Sun X; Hillard CJ; Liu QS
Neuropsychopharmacology; 2010 Oct; 35(11):2249-61. PubMed ID: 20664582
[TBL] [Abstract][Full Text] [Related]
10. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.
Dowie MJ; Bradshaw HB; Howard ML; Nicholson LF; Faull RL; Hannan AJ; Glass M
Neuroscience; 2009 Sep; 163(1):456-65. PubMed ID: 19524019
[TBL] [Abstract][Full Text] [Related]
11. Endocannabinoids in the treatment of mood disorders: evidence from animal models.
Bambico FR; Duranti A; Tontini A; Tarzia G; Gobbi G
Curr Pharm Des; 2009; 15(14):1623-46. PubMed ID: 19442178
[TBL] [Abstract][Full Text] [Related]
12. The cannabinoid CB1 receptor and the endocannabinoid anandamide: possible antidepressant targets.
Bambico FR; Gobbi G
Expert Opin Ther Targets; 2008 Nov; 12(11):1347-66. PubMed ID: 18851692
[TBL] [Abstract][Full Text] [Related]
13. Local enhancement of cannabinoid CB1 receptor signalling in the dorsal hippocampus elicits an antidepressant-like effect.
McLaughlin RJ; Hill MN; Morrish AC; Gorzalka BB
Behav Pharmacol; 2007 Sep; 18(5-6):431-8. PubMed ID: 17762511
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of CB₁ receptor binding in the ventromedial prefrontal cortex promotes proactive stress-coping strategies following chronic stress exposure.
McLaughlin RJ; Hill MN; Dang SS; Wainwright SR; Galea LA; Hillard CJ; Gorzalka BB
Behav Brain Res; 2013 Jan; 237():333-7. PubMed ID: 23047058
[TBL] [Abstract][Full Text] [Related]
15. Endocannabinoid modulation of male rat sexual behavior.
Gorzalka BB; Morrish AC; Hill MN
Psychopharmacology (Berl); 2008 Jul; 198(4):479-86. PubMed ID: 17694389
[TBL] [Abstract][Full Text] [Related]
16. Dysfunction in fatty acid amide hydrolase is associated with depressive-like behavior in Wistar Kyoto rats.
Vinod KY; Xie S; Psychoyos D; Hungund BL; Cooper TB; Tejani-Butt SM
PLoS One; 2012; 7(5):e36743. PubMed ID: 22606285
[TBL] [Abstract][Full Text] [Related]
17. Effect of chronic ethanol exposure and its withdrawal on the endocannabinoid system.
Vinod KY; Yalamanchili R; Xie S; Cooper TB; Hungund BL
Neurochem Int; 2006 Nov; 49(6):619-25. PubMed ID: 16822589
[TBL] [Abstract][Full Text] [Related]
18. Actions of the endocannabinoid transport inhibitor AM404 in neuropathic and inflammatory pain models.
Mitchell VA; Greenwood R; Jayamanne A; Vaughan CW
Clin Exp Pharmacol Physiol; 2007 Nov; 34(11):1186-90. PubMed ID: 17880375
[TBL] [Abstract][Full Text] [Related]
19. Chronic, noninvasive glucocorticoid administration suppresses limbic endocannabinoid signaling in mice.
Bowles NP; Hill MN; Bhagat SM; Karatsoreos IN; Hillard CJ; McEwen BS
Neuroscience; 2012 Mar; 204():83-9. PubMed ID: 21939741
[TBL] [Abstract][Full Text] [Related]
20. Anxiolytic-like properties of the anandamide transport inhibitor AM404.
Bortolato M; Campolongo P; Mangieri RA; Scattoni ML; Frau R; Trezza V; La Rana G; Russo R; Calignano A; Gessa GL; Cuomo V; Piomelli D
Neuropsychopharmacology; 2006 Dec; 31(12):2652-9. PubMed ID: 16541083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
